| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyrimidines | 22 | 2021 | 128 | 3.020 |
Why?
|
| Antineoplastic Agents | 19 | 2021 | 686 | 1.780 |
Why?
|
| Indoles | 7 | 2017 | 110 | 1.560 |
Why?
|
| Angiogenesis Inhibitors | 18 | 2017 | 108 | 1.530 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2021 | 165 | 1.370 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 11 | 2021 | 56 | 1.340 |
Why?
|
| Cell Line, Tumor | 30 | 2021 | 1350 | 1.130 |
Why?
|
| Neoplasm Micrometastasis | 2 | 2015 | 6 | 0.900 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 10 | 2017 | 51 | 0.860 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2010 | 125 | 0.850 |
Why?
|
| Blood Glucose | 7 | 2010 | 310 | 0.810 |
Why?
|
| Breast Neoplasms | 7 | 2015 | 482 | 0.800 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2016 | 59 | 0.760 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 8 | 2018 | 21 | 0.710 |
Why?
|
| Pyrroles | 6 | 2017 | 36 | 0.710 |
Why?
|
| Drug Design | 6 | 2018 | 63 | 0.710 |
Why?
|
| Microtubules | 5 | 2021 | 90 | 0.660 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2010 | 344 | 0.660 |
Why?
|
| Animals | 51 | 2021 | 10684 | 0.650 |
Why?
|
| Mice | 34 | 2021 | 4802 | 0.640 |
Why?
|
| Endothelium, Vascular | 10 | 2011 | 334 | 0.630 |
Why?
|
| Oxidative Stress | 11 | 2010 | 677 | 0.610 |
Why?
|
| Diamines | 3 | 2013 | 6 | 0.570 |
Why?
|
| Hyperglycemia | 6 | 2010 | 78 | 0.550 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2013 | 166 | 0.550 |
Why?
|
| Cell Proliferation | 16 | 2021 | 824 | 0.530 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 164 | 0.520 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 13 | 0.520 |
Why?
|
| Drug Resistance, Multiple | 3 | 2005 | 20 | 0.510 |
Why?
|
| Lung Neoplasms | 3 | 2014 | 360 | 0.500 |
Why?
|
| Mice, Nude | 13 | 2020 | 332 | 0.480 |
Why?
|
| Arsenic | 6 | 2010 | 19 | 0.480 |
Why?
|
| Humans | 58 | 2021 | 28851 | 0.470 |
Why?
|
| Necrosis | 1 | 2015 | 85 | 0.440 |
Why?
|
| Phenotype | 3 | 2013 | 685 | 0.440 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 36 | 0.440 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 117 | 0.420 |
Why?
|
| Diabetic Angiopathies | 2 | 2010 | 48 | 0.400 |
Why?
|
| Mitochondria | 2 | 2015 | 408 | 0.400 |
Why?
|
| Cell Culture Techniques | 6 | 2013 | 117 | 0.370 |
Why?
|
| Structure-Activity Relationship | 14 | 2021 | 209 | 0.360 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 148 | 0.350 |
Why?
|
| Drug Screening Assays, Antitumor | 12 | 2021 | 103 | 0.350 |
Why?
|
| Diabetes Complications | 2 | 2008 | 66 | 0.330 |
Why?
|
| Oxygen | 4 | 2011 | 237 | 0.330 |
Why?
|
| Melanoma, Experimental | 4 | 2013 | 31 | 0.330 |
Why?
|
| Hypoglycemia | 1 | 2010 | 34 | 0.320 |
Why?
|
| CD13 Antigens | 4 | 2013 | 26 | 0.310 |
Why?
|
| Glucose | 2 | 2008 | 209 | 0.300 |
Why?
|
| Tubulin Modulators | 2 | 2021 | 17 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 275 | 0.280 |
Why?
|
| Technetium | 3 | 2013 | 43 | 0.280 |
Why?
|
| Oligopeptides | 3 | 2013 | 97 | 0.280 |
Why?
|
| Molecular Structure | 11 | 2021 | 245 | 0.280 |
Why?
|
| Intestinal Mucosa | 2 | 2010 | 198 | 0.280 |
Why?
|
| Mitomycin | 4 | 2005 | 19 | 0.270 |
Why?
|
| Chick Embryo | 15 | 2015 | 27 | 0.270 |
Why?
|
| Neoplasms, Experimental | 6 | 2021 | 58 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2012 | 179 | 0.270 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2007 | 11 | 0.260 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 278 | 0.260 |
Why?
|
| Apoptosis | 6 | 2015 | 780 | 0.260 |
Why?
|
| Glioma | 2 | 2020 | 122 | 0.260 |
Why?
|
| Cell Movement | 3 | 2015 | 376 | 0.260 |
Why?
|
| Rats | 8 | 2015 | 1588 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2006 | 104 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 147 | 0.250 |
Why?
|
| Doxorubicin | 5 | 2014 | 77 | 0.240 |
Why?
|
| Hypoxia | 1 | 2006 | 90 | 0.240 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 292 | 0.230 |
Why?
|
| Drug Discovery | 2 | 2016 | 37 | 0.230 |
Why?
|
| Laminin | 1 | 2005 | 21 | 0.230 |
Why?
|
| Proteoglycans | 1 | 2005 | 38 | 0.220 |
Why?
|
| Drug Combinations | 1 | 2005 | 50 | 0.220 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 312 | 0.220 |
Why?
|
| Female | 17 | 2020 | 15624 | 0.220 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 35 | 0.220 |
Why?
|
| ErbB Receptors | 8 | 2021 | 100 | 0.220 |
Why?
|
| Transcription Factors | 3 | 2005 | 523 | 0.210 |
Why?
|
| Thymidylate Synthase | 2 | 2017 | 7 | 0.210 |
Why?
|
| Collagen | 1 | 2005 | 156 | 0.210 |
Why?
|
| Neovascularization, Physiologic | 5 | 2015 | 124 | 0.200 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 251 | 0.200 |
Why?
|
| Cystitis | 3 | 2007 | 11 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2017 | 198 | 0.200 |
Why?
|
| Signal Transduction | 7 | 2017 | 1469 | 0.200 |
Why?
|
| Gene Expression | 4 | 2013 | 417 | 0.200 |
Why?
|
| Models, Molecular | 9 | 2021 | 452 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 612 | 0.190 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 404 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 8 | 2020 | 314 | 0.180 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 1507 | 0.180 |
Why?
|
| Gene Expression Regulation | 4 | 2012 | 634 | 0.180 |
Why?
|
| Urinary Bladder | 5 | 2010 | 119 | 0.180 |
Why?
|
| Lung | 4 | 2009 | 382 | 0.170 |
Why?
|
| Quinazolines | 1 | 2021 | 32 | 0.170 |
Why?
|
| Cyclopentanes | 1 | 2020 | 17 | 0.170 |
Why?
|
| Male | 17 | 2020 | 13921 | 0.160 |
Why?
|
| Tumor Burden | 2 | 2013 | 110 | 0.150 |
Why?
|
| Curcumin | 2 | 2010 | 69 | 0.150 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 60 | 0.150 |
Why?
|
| Coal | 1 | 2018 | 11 | 0.150 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2015 | 34 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2012 | 1022 | 0.140 |
Why?
|
| Carboplatin | 1 | 1999 | 121 | 0.140 |
Why?
|
| Cell Line | 5 | 2018 | 700 | 0.140 |
Why?
|
| Water Supply | 2 | 2009 | 35 | 0.140 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 9 | 0.140 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Receptors, GABA-A | 1 | 2017 | 18 | 0.140 |
Why?
|
| Water Pollutants, Chemical | 2 | 2009 | 55 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 123 | 0.140 |
Why?
|
| Mitomycins | 1 | 1997 | 2 | 0.140 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 2 | 2009 | 29 | 0.140 |
Why?
|
| Water | 2 | 2018 | 135 | 0.130 |
Why?
|
| Cross-Linking Reagents | 1 | 1997 | 43 | 0.130 |
Why?
|
| Receptor, PAR-1 | 2 | 2007 | 7 | 0.130 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 9 | 0.130 |
Why?
|
| Chorioallantoic Membrane | 4 | 2013 | 7 | 0.130 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 4 | 0.130 |
Why?
|
| Gene Regulatory Networks | 2 | 2007 | 82 | 0.130 |
Why?
|
| Keratinocytes | 1 | 2017 | 33 | 0.130 |
Why?
|
| Kidney | 1 | 2018 | 289 | 0.130 |
Why?
|
| Blotting, Western | 5 | 2012 | 515 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2007 | 95 | 0.120 |
Why?
|
| Disease Progression | 2 | 2017 | 477 | 0.120 |
Why?
|
| Homeostasis | 2 | 2015 | 119 | 0.120 |
Why?
|
| Arsenites | 2 | 2007 | 4 | 0.120 |
Why?
|
| Calcium | 2 | 2015 | 243 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2017 | 302 | 0.120 |
Why?
|
| Binding Sites | 3 | 2012 | 355 | 0.120 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2015 | 45 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 34 | 0.120 |
Why?
|
| Furans | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2013 | 126 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 30 | 0.110 |
Why?
|
| Cell Membrane Permeability | 1 | 2015 | 44 | 0.110 |
Why?
|
| Hypoglycemic Agents | 3 | 2010 | 110 | 0.110 |
Why?
|
| Superoxides | 1 | 2015 | 62 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 328 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 433 | 0.110 |
Why?
|
| Cell Survival | 5 | 2013 | 419 | 0.110 |
Why?
|
| Aniline Compounds | 1 | 2014 | 23 | 0.110 |
Why?
|
| Inflammation | 2 | 2010 | 667 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 48 | 0.110 |
Why?
|
| Retina | 2 | 2008 | 445 | 0.100 |
Why?
|
| Fibrosarcoma | 1 | 2013 | 12 | 0.100 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 122 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2007 | 485 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 23 | 0.100 |
Why?
|
| Vimentin | 1 | 2013 | 28 | 0.100 |
Why?
|
| Materials Testing | 3 | 2010 | 89 | 0.100 |
Why?
|
| Heterografts | 1 | 2013 | 66 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 2 | 2012 | 97 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 37 | 0.100 |
Why?
|
| Halogenation | 1 | 2013 | 7 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2013 | 35 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2013 | 87 | 0.100 |
Why?
|
| Glycated Hemoglobin A | 2 | 2010 | 64 | 0.100 |
Why?
|
| Time Factors | 2 | 2015 | 1613 | 0.100 |
Why?
|
| Cisplatin | 3 | 2017 | 186 | 0.100 |
Why?
|
| Molecular Docking Simulation | 3 | 2018 | 53 | 0.100 |
Why?
|
| Indenes | 1 | 2012 | 2 | 0.100 |
Why?
|
| Blood Vessels | 2 | 2003 | 58 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 40 | 0.090 |
Why?
|
| Dermis | 1 | 2012 | 4 | 0.090 |
Why?
|
| Propionates | 1 | 2012 | 11 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 9 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 11 | 0.090 |
Why?
|
| Folic Acid Antagonists | 2 | 2017 | 17 | 0.090 |
Why?
|
| Osteoclasts | 1 | 2012 | 32 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 82 | 0.090 |
Why?
|
| Retinal Neovascularization | 1 | 2011 | 21 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 24 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 284 | 0.090 |
Why?
|
| Serpins | 1 | 2011 | 31 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 81 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2012 | 160 | 0.090 |
Why?
|
| Receptors, Proteinase-Activated | 2 | 2007 | 3 | 0.080 |
Why?
|
| Glycation End Products, Advanced | 2 | 2008 | 17 | 0.080 |
Why?
|
| Urothelium | 2 | 2007 | 35 | 0.080 |
Why?
|
| Liver | 2 | 2008 | 471 | 0.080 |
Why?
|
| Polyglycolic Acid | 1 | 2010 | 38 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 7 | 2009 | 1653 | 0.080 |
Why?
|
| Stem Cells | 1 | 2011 | 123 | 0.080 |
Why?
|
| Diabetic Retinopathy | 2 | 2011 | 112 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2010 | 66 | 0.080 |
Why?
|
| Curcuma | 1 | 2010 | 8 | 0.080 |
Why?
|
| Critical Care | 1 | 2010 | 49 | 0.080 |
Why?
|
| Immunoprecipitation | 2 | 2007 | 68 | 0.080 |
Why?
|
| RNA, Messenger | 5 | 2009 | 668 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2010 | 94 | 0.080 |
Why?
|
| Eye Proteins | 1 | 2011 | 207 | 0.080 |
Why?
|
| Neoplasm Transplantation | 2 | 2010 | 90 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 103 | 0.080 |
Why?
|
| PPAR alpha | 1 | 2009 | 34 | 0.070 |
Why?
|
| Chromium | 2 | 1999 | 13 | 0.070 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 71 | 0.070 |
Why?
|
| Immune System | 1 | 2009 | 29 | 0.070 |
Why?
|
| Thrombin | 1 | 2009 | 69 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 296 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 53 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2008 | 50 | 0.070 |
Why?
|
| Gliclazide | 1 | 2008 | 1 | 0.070 |
Why?
|
| Apolipoprotein B-100 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Animal Feed | 1 | 2008 | 21 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2009 | 109 | 0.070 |
Why?
|
| Prognosis | 1 | 2010 | 811 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2007 | 14 | 0.070 |
Why?
|
| GTP Phosphohydrolases | 1 | 2007 | 19 | 0.070 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 42 | 0.070 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2007 | 4 | 0.070 |
Why?
|
| Sodium Compounds | 1 | 2007 | 2 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2007 | 15 | 0.070 |
Why?
|
| HLA Antigens | 1 | 2007 | 61 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2007 | 61 | 0.070 |
Why?
|
| Chitosan | 1 | 2007 | 34 | 0.070 |
Why?
|
| Polyesters | 1 | 2007 | 35 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2009 | 194 | 0.070 |
Why?
|
| Neoplasms | 2 | 2012 | 874 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2007 | 82 | 0.070 |
Why?
|
| Glycosylation | 1 | 2007 | 70 | 0.070 |
Why?
|
| Protein C Inhibitor | 1 | 2007 | 5 | 0.070 |
Why?
|
| Vasodilation | 1 | 2008 | 115 | 0.070 |
Why?
|
| Biological Assay | 1 | 2007 | 34 | 0.070 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2007 | 16 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 9 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2007 | 39 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2010 | 291 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 153 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2007 | 98 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 140 | 0.060 |
Why?
|
| Aorta | 1 | 2007 | 124 | 0.060 |
Why?
|
| Chorion | 2 | 2003 | 4 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 170 | 0.060 |
Why?
|
| Gene Expression Profiling | 4 | 2009 | 465 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 224 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2012 | 585 | 0.060 |
Why?
|
| Risk Factors | 1 | 2010 | 2126 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 472 | 0.050 |
Why?
|
| Metals | 2 | 2018 | 41 | 0.050 |
Why?
|
| Myocardium | 1 | 2005 | 196 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 548 | 0.050 |
Why?
|
| Hydroxyquinolines | 1 | 2003 | 3 | 0.050 |
Why?
|
| Mutation | 1 | 2006 | 867 | 0.050 |
Why?
|
| Thalidomide | 1 | 2002 | 14 | 0.050 |
Why?
|
| Toxicity Tests | 2 | 2018 | 11 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2012 | 874 | 0.040 |
Why?
|
| DNA Adducts | 2 | 1999 | 6 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2020 | 67 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2011 | 9 | 0.040 |
Why?
|
| Ascorbic Acid | 2 | 2010 | 24 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 29 | 0.040 |
Why?
|
| Mercury | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 1999 | 138 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1999 | 79 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2018 | 54 | 0.040 |
Why?
|
| Methylcholanthrene | 1 | 1998 | 2 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 1998 | 4 | 0.040 |
Why?
|
| Xenobiotics | 1 | 1998 | 5 | 0.040 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 1998 | 11 | 0.040 |
Why?
|
| Genetic Markers | 1 | 1998 | 92 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1998 | 35 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1998 | 57 | 0.040 |
Why?
|
| Endonucleases | 1 | 1998 | 17 | 0.030 |
Why?
|
| Insulin | 2 | 2010 | 325 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 94 | 0.030 |
Why?
|
| United States | 2 | 2018 | 2222 | 0.030 |
Why?
|
| Paclitaxel | 1 | 1999 | 200 | 0.030 |
Why?
|
| Verapamil | 1 | 1997 | 9 | 0.030 |
Why?
|
| Carbon | 1 | 2018 | 107 | 0.030 |
Why?
|
| K562 Cells | 1 | 1997 | 20 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 34 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 22 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 129 | 0.030 |
Why?
|
| Genome | 2 | 2008 | 56 | 0.030 |
Why?
|
| DNA Repair | 1 | 1998 | 82 | 0.030 |
Why?
|
| Substance P | 2 | 2007 | 6 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 257 | 0.030 |
Why?
|
| Chickens | 2 | 2007 | 62 | 0.030 |
Why?
|
| Cell Division | 3 | 2003 | 154 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2017 | 7 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2017 | 18 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 36 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1997 | 56 | 0.030 |
Why?
|
| Antigens | 2 | 2007 | 68 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 182 | 0.030 |
Why?
|
| DNA Damage | 1 | 1997 | 152 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2007 | 157 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1997 | 133 | 0.030 |
Why?
|
| Allantois | 2 | 2007 | 2 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 249 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 1997 | 167 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2015 | 15 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 14 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 51 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 288 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 242 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 73 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 212 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 61 | 0.030 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2013 | 4 | 0.030 |
Why?
|
| Betaine | 1 | 1993 | 4 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2007 | 163 | 0.020 |
Why?
|
| Microwaves | 1 | 2013 | 10 | 0.020 |
Why?
|
| Middle Aged | 3 | 2008 | 7414 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 82 | 0.020 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2012 | 2 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2012 | 6 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2012 | 6 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2012 | 9 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2012 | 19 | 0.020 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 44 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 40 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2012 | 14 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 55 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2012 | 39 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 88 | 0.020 |
Why?
|
| Indazoles | 1 | 2012 | 18 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 69 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 2003 | 164 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2011 | 137 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 93 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 267 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 101 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 247 | 0.020 |
Why?
|
| Acetylcholinesterase | 1 | 1970 | 4 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 198 | 0.020 |
Why?
|
| Atropine | 1 | 1970 | 47 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 18 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 16 | 0.020 |
Why?
|
| src Homology Domains | 1 | 2010 | 31 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2010 | 22 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2010 | 30 | 0.020 |
Why?
|
| Regeneration | 1 | 2010 | 77 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2010 | 79 | 0.020 |
Why?
|
| Leukemia | 1 | 2010 | 30 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 36 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 510 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 513 | 0.020 |
Why?
|
| Cattle | 1 | 2011 | 389 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 238 | 0.020 |
Why?
|
| Clofibrate | 1 | 2009 | 4 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 202 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 26 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2009 | 51 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 427 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 131 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2008 | 12 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 232 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 222 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 178 | 0.020 |
Why?
|
| Melanoma | 1 | 2010 | 140 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 60 | 0.020 |
Why?
|
| Glyburide | 1 | 2008 | 4 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 776 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2008 | 25 | 0.020 |
Why?
|
| Pericytes | 1 | 2008 | 17 | 0.020 |
Why?
|
| Oscillometry | 1 | 2008 | 4 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 45 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 43 | 0.020 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 7 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 50 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 58 | 0.020 |
Why?
|
| Somatostatin | 1 | 2008 | 25 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2008 | 74 | 0.020 |
Why?
|
| Food Contamination | 1 | 2008 | 22 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2007 | 8 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 2007 | 14 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 46 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 29 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2007 | 10 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 200 | 0.020 |
Why?
|
| Mast Cells | 1 | 2007 | 9 | 0.020 |
Why?
|
| Porosity | 1 | 2007 | 38 | 0.020 |
Why?
|
| Acetic Acid | 1 | 2007 | 28 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2008 | 56 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2007 | 28 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 58 | 0.020 |
Why?
|
| Immunity | 1 | 2007 | 27 | 0.020 |
Why?
|
| Phospholipases A | 1 | 2007 | 6 | 0.020 |
Why?
|
| Receptor, PAR-2 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 22 | 0.020 |
Why?
|
| Surface Properties | 1 | 2007 | 134 | 0.020 |
Why?
|
| Granulocytes | 1 | 2007 | 6 | 0.020 |
Why?
|
| Edema | 1 | 2007 | 18 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 128 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 196 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 380 | 0.020 |
Why?
|
| Protein Binding | 2 | 1999 | 667 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 524 | 0.020 |
Why?
|
| Chromatin | 1 | 2007 | 76 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 270 | 0.020 |
Why?
|
| Adult | 2 | 2009 | 8024 | 0.020 |
Why?
|
| Computational Biology | 1 | 2007 | 156 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 469 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2007 | 150 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2007 | 152 | 0.010 |
Why?
|
| Methotrexate | 1 | 2005 | 36 | 0.010 |
Why?
|
| Macrophages | 1 | 2008 | 305 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 631 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 377 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 58 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 106 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 121 | 0.010 |
Why?
|
| Allantoin | 1 | 2003 | 1 | 0.010 |
Why?
|
| Membranes | 1 | 2003 | 8 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 180 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2833 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 77 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2002 | 5 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2002 | 9 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 10 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 2002 | 11 | 0.010 |
Why?
|
| KB Cells | 1 | 1999 | 1 | 0.010 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1999 | 28 | 0.010 |
Why?
|
| Gelatin | 1 | 1999 | 11 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 147 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1998 | 48 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1998 | 28 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 78 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 588 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 1998 | 1 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1998 | 51 | 0.010 |
Why?
|
| Aged | 1 | 2008 | 5598 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 96 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 131 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 120 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1998 | 344 | 0.010 |
Why?
|
| Proteins | 1 | 1998 | 254 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1998 | 490 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1993 | 17 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 25 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 1970 | 13 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1970 | 22 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 1970 | 10 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1993 | 338 | 0.010 |
Why?
|